To examine the clinical effects of intravitreal bevacizumab injections for patients with macular edema secondary to branched retinal vein occlusion (BRVO).

Nineteen patients (19 eyes) diagnosed with BRVO within the three month study window, having visual acuities under 0.5 and significant macular edema within two-disc diameters of the fovea were included in the present study. The author evaluated the patients' responses to bevacizumab (1.25 mg/0.05 mL) treatment using visual acuity and central macular edema measurements.

The mean visual acuity improved from 1.06 (±0.10 logMAR unit) at baseline to 0.68 (±0.09 logMAR unit), 0.279 (±0.049) at one month, 0.67 (±0.9 logMAR unit) at two months, 0.61 (±0.09 logMAR unit) at three months and 0.54 (±0.10 logMAR unit) at six months. The mean central macular thickness decreased from 552.9 µm (±41.0) at baseline to 290.0 µm (±36.7) at one month, 290.0 µm (±36.7) at three months and 281.3 µm (±30.1) at six months. No adverse side effects were observed following injections.

The observed macular edema and visual acuity improvements, as well as lack of serious adverse side effects after intravitreal bevacizumab injection, demonstrated that intravitreal bevacizumab injection may be useful for treating patients with macular edema secondary to BRVO.